[go: up one dir, main page]

EP1377287A4 - Proanthocyanidines destinees au traitement des amyloses et des maladies induites par alpha-synucleine - Google Patents

Proanthocyanidines destinees au traitement des amyloses et des maladies induites par alpha-synucleine

Info

Publication number
EP1377287A4
EP1377287A4 EP02719009A EP02719009A EP1377287A4 EP 1377287 A4 EP1377287 A4 EP 1377287A4 EP 02719009 A EP02719009 A EP 02719009A EP 02719009 A EP02719009 A EP 02719009A EP 1377287 A4 EP1377287 A4 EP 1377287A4
Authority
EP
European Patent Office
Prior art keywords
proanthocyanidins
amyloid
alpha
treatment
synuclein diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02719009A
Other languages
German (de)
English (en)
Other versions
EP1377287A2 (fr
Inventor
Alan D Snow
Geraldo M Castillo
Paula Y Choi
Beth P Nguyen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ProteoTech Inc
Original Assignee
ProteoTech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/938,987 external-priority patent/US6607758B2/en
Priority claimed from US10/053,625 external-priority patent/US6929808B2/en
Application filed by ProteoTech Inc filed Critical ProteoTech Inc
Publication of EP1377287A2 publication Critical patent/EP1377287A2/fr
Publication of EP1377287A4 publication Critical patent/EP1377287A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
EP02719009A 2001-03-15 2002-02-15 Proanthocyanidines destinees au traitement des amyloses et des maladies induites par alpha-synucleine Withdrawn EP1377287A4 (fr)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US938987 1997-09-26
US27686601P 2001-03-15 2001-03-15
US276866P 2001-03-15
US09/938,987 US6607758B2 (en) 1997-05-15 2001-08-24 Methods for inhibiting and reducing amyloid fibril formation associated with Alzheimer's Disease and other amyloidoses
US10/053,625 US6929808B2 (en) 2000-11-03 2001-11-02 Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from Uncaria tomentosa and related plants
PCT/US2001/051131 WO2002042429A2 (fr) 2000-11-03 2001-11-02 Procedes d'isolement de composes inhibiteurs d'amyloide, et utilisation de composes utilises a partir d'uncaria tomentosa et de plantes parentes
US53625 2001-11-02
WOPCT/US05/01131 2001-11-02
US33872101P 2001-12-04 2001-12-04
US338721P 2001-12-04
US33903301P 2001-12-10 2001-12-10
US33896901P 2001-12-10 2001-12-10
US339033P 2001-12-10
US338969P 2001-12-10
PCT/US2002/004764 WO2002076381A2 (fr) 2001-03-15 2002-02-15 Proanthocyanidines destinees au traitement des amyloses et des maladies induites par alpha-synucleine

Publications (2)

Publication Number Publication Date
EP1377287A2 EP1377287A2 (fr) 2004-01-07
EP1377287A4 true EP1377287A4 (fr) 2007-11-14

Family

ID=56290250

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02719009A Withdrawn EP1377287A4 (fr) 2001-03-15 2002-02-15 Proanthocyanidines destinees au traitement des amyloses et des maladies induites par alpha-synucleine

Country Status (6)

Country Link
EP (1) EP1377287A4 (fr)
JP (1) JP4380991B2 (fr)
AU (1) AU2002250117B2 (fr)
CA (1) CA2441099C (fr)
NZ (1) NZ528322A (fr)
WO (1) WO2002076381A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7514583B2 (en) * 2002-05-31 2009-04-07 Proteotech, Inc. Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes, and parkinson's disease
US20070208087A1 (en) 2001-11-02 2007-09-06 Sanders Virginia J Compounds, compositions and methods for the treatment of inflammatory diseases
US7514107B2 (en) 2002-03-21 2009-04-07 Mars, Incorporated Treatment of diseases involving defective gap junctional communication
AU2003279213B2 (en) * 2002-10-11 2008-12-18 Cognitive Clarity Inc. Isolation, purification and synthesis of procyanidin B2 and uses thereof
JP2006232670A (ja) * 2003-05-20 2006-09-07 Ajinomoto Co Inc 神経障害用薬剤
JP4505555B2 (ja) * 2004-03-02 2010-07-21 康 大泉 神経変性疾患治療剤
CN101460157B (zh) * 2006-03-29 2015-09-02 维斯塔实验室有限公司 蛋白聚集抑制剂
JP5443015B2 (ja) * 2008-02-19 2014-03-19 株式会社岐阜セラツク製造所 医薬組成物
CN102083444A (zh) * 2008-05-09 2011-06-01 西奈山医学院 用于预防和治疗神经退行性疾病的方法
US20140179774A1 (en) * 2012-12-26 2014-06-26 Industrial Technology Research Institute Methods for inhibition of shc-1/p66 to combat aging-related diseases
JP6894838B2 (ja) 2015-05-11 2021-06-30 株式会社明治 脳由来神経栄養因子の産生促進用組成物
KR102441381B1 (ko) * 2016-07-18 2022-09-07 (주)아모레퍼시픽 3-O-갈로일-3,3',5,5',7-펜타하이드록시플라반(3-O-galloyl-3,3',5,5',7- pentahydroxyflavan)을 포함하는 인지 기능 개선용 조성물
WO2021193703A1 (fr) * 2020-03-24 2021-09-30 学校法人 芝浦工業大学 Composition de potentialisation du système nerveux central

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922756A (en) * 1998-02-14 1999-07-13 Chan; Marion Man-Ying Method of inhibiting nitric oxide synthase
WO1999045797A1 (fr) * 1998-03-12 1999-09-16 Mars, Incorporated Produits contenant du ou des polyphenols et de l'arginine-l favorisant la production d'oxyde nitrique
WO2000030666A1 (fr) * 1998-11-24 2000-06-02 University Of Washington Composition et procedes pour inhiber la formation de depots de substances amyloides dans le cerveau
WO2001049307A1 (fr) * 1999-12-30 2001-07-12 Proteotech, Inc. Catechines et extrait de the vert destines au traitement de l'amyloidose dans la maladie d'alzheimer et d'autres amyloidoses

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4698360B1 (en) * 1985-04-09 1997-11-04 D Investigations Pharmacologiq Plant extract with a proanthocyanidins content as therapeutic agent having radical scavenger effect and use thereof
US6939570B1 (en) * 1997-05-15 2005-09-06 University Of Washington Composition and methods for treating Alzheimer's disease and other amyloidoses
WO2000057707A1 (fr) * 1999-03-15 2000-10-05 Proteotech, Inc. Methodes de traitement de la maladie d'alzheimer et d'autres amyloses avec l'hypericum perforatum et ses derives

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922756A (en) * 1998-02-14 1999-07-13 Chan; Marion Man-Ying Method of inhibiting nitric oxide synthase
WO1999045797A1 (fr) * 1998-03-12 1999-09-16 Mars, Incorporated Produits contenant du ou des polyphenols et de l'arginine-l favorisant la production d'oxyde nitrique
WO2000030666A1 (fr) * 1998-11-24 2000-06-02 University Of Washington Composition et procedes pour inhiber la formation de depots de substances amyloides dans le cerveau
WO2001049307A1 (fr) * 1999-12-30 2001-07-12 Proteotech, Inc. Catechines et extrait de the vert destines au traitement de l'amyloidose dans la maladie d'alzheimer et d'autres amyloidoses

Also Published As

Publication number Publication date
AU2002250117B2 (en) 2007-11-29
CA2441099C (fr) 2011-04-19
WO2002076381A2 (fr) 2002-10-03
NZ528322A (en) 2005-03-24
AU2002250117B8 (en) 2002-10-08
EP1377287A2 (fr) 2004-01-07
CA2441099A1 (fr) 2002-10-03
JP2005505497A (ja) 2005-02-24
WO2002076381A3 (fr) 2002-11-21
JP4380991B2 (ja) 2009-12-09

Similar Documents

Publication Publication Date Title
IL159344A0 (en) Quinuclidines-substituted-multicyclic-heteroaryls for the treatment of disease
AU7186501A (en) Methods for preventing neural tissue damage and for the treatment of alpha-synuclein diseases
EP1578421A4 (fr) Preparations pharmaceutiques permettant le traitement de maladies et d'affections du sein
IL161267A0 (en) Combinations for the treatment of immunoinflammatory disorders
HUP0400314A3 (en) Pharmaceutical combinations for the treatment of cancer
PL366636A1 (en) Pyranoindazoles and their use for the treatment of glaucoma
AU2002346504A8 (en) Therapeutic protein and treatments
IL159887A0 (en) Combination therapy for the treatment of cancer
HUP0400024A3 (en) Combination for treatment of neoplastic diseases
EP1377287A4 (fr) Proanthocyanidines destinees au traitement des amyloses et des maladies induites par alpha-synucleine
GB0004531D0 (en) The treatment of respiratory diseases
EP1416795A4 (fr) Compositions et procedes pour le traitement de maladies mitochondriales
HRP20030609A2 (en) Use of il-18 inhibitors for the treatment and/or prevention of heart disease
EP1472273A4 (fr) Compositions et methodes de traitement de maladies d'origine immune
EP1406600A4 (fr) Compositions et methodes d'administration d'agents de fixation a la tubuline dans le traitement de maladies oculaires
IL144949A0 (en) Treatment of prion diseases with dmso
GB0101146D0 (en) Treatment of skin conditions
AU2908501A (en) Combination therapy for the treatment of inflammatory and respiratory diseases
NO20042166L (no) Kombinasjonsterapi for behandling av sykdom
GB0222282D0 (en) Therapeutic device for the treatment of symptons caused by diseases
AU2002365654A8 (en) Treatment of diseases via the skin
AU2728301A (en) Combination therapy for the treatment of inflammatory and respiratory diseases
HU0105291D0 (en) Pharmaceutical compositions for the treatment of indigestion and related diseases
GB0108892D0 (en) The treatment of respiratory diseases
GC0000285A (en) Herbal composition for the treatment of skin disorder

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030924

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: NGUYEN, BETH, P.

Inventor name: CHOI, PAULA, Y.

Inventor name: CASTILLO, GERALDO, M.

Inventor name: SNOW, ALAN, D.

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 3/10 20060101ALI20070717BHEP

Ipc: A61P 25/28 20060101ALI20070717BHEP

Ipc: A61P 25/16 20060101ALI20070717BHEP

Ipc: A61K 31/353 20060101ALI20070717BHEP

Ipc: A61K 31/352 20060101ALI20070717BHEP

Ipc: A61K 31/35 20060101AFI20070717BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20071016

17Q First examination report despatched

Effective date: 20090618

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120925